MedPath
Found 73 clinical trials|View Analysis
Sort by:

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Not Applicable
Not yet recruiting
Conditions
Mismatch Repair Deficiency
Endometrioid Carcinoma
Endometrial Cancer
Interventions
First Posted Date
2024-08-12
Last Posted Date
2024-08-12
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
10
Registration Number
NCT06549855
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

Nutrition Impact on Immunotherapy of Cancer

Phase 3
Recruiting
Conditions
Nutrition Disorders
Cancer
Survival, Prosthesis
Immunotherapy
Interventions
Drug: Megestrol Acetate and olanzapine
Drug: Starch powder 50 mg
First Posted Date
2024-07-15
Last Posted Date
2024-07-15
Lead Sponsor
Qingdao Central Hospital
Target Recruit Count
300
Registration Number
NCT06500234
Locations
🇨🇳

Qingdao Central Hospital, Qingdao, Shandong, China

Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women

Not Applicable
Recruiting
Conditions
Endometrial Hyperplasia
Endometrial Cancer Stage I
Interventions
Drug: Megestrol Acetate 40 MG
First Posted Date
2024-05-16
Last Posted Date
2024-05-16
Lead Sponsor
Women's Hospital School Of Medicine Zhejiang University
Target Recruit Count
75
Registration Number
NCT06417736
Locations
🇨🇳

Women's Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China

Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)

Phase 2
Recruiting
Conditions
Adrenocortical Carcinoma
Interventions
Drug: Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG
Drug: Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
First Posted Date
2023-06-22
Last Posted Date
2024-08-01
Lead Sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Target Recruit Count
80
Registration Number
NCT05913427
Locations
🇮🇹

Alfredo Berruti, Brescia, Italy

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Phase 1
Recruiting
Conditions
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Metastatic Endometrial Endometrioid Adenocarcinoma
Recurrent Endometrial Endometrioid Adenocarcinoma
Interventions
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ipatasertib
Procedure: Magnetic Resonance Imaging
Drug: Megestrol Acetate
First Posted Date
2022-09-14
Last Posted Date
2025-01-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
96
Registration Number
NCT05538897
Locations
🇺🇸

Parkview Regional Medical Center, Fort Wayne, Indiana, United States

🇺🇸

Banner University Medical Center - Tucson, Tucson, Arizona, United States

🇺🇸

University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

and more 116 locations

Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients.

Phase 2
Conditions
Anorexia
Interventions
First Posted Date
2022-05-18
Last Posted Date
2022-05-18
Lead Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Target Recruit Count
80
Registration Number
NCT05380479
Locations
🇧🇩

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer

Phase 1
Terminated
Conditions
Endometrial Cancer
Interventions
First Posted Date
2022-04-18
Last Posted Date
2023-11-03
Lead Sponsor
Sunnybrook Health Sciences Centre
Target Recruit Count
5
Registration Number
NCT05332483
Locations
🇨🇦

Sunnybrook Health Sciences, Toronto, Ontario, Canada

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

Phase 2
Recruiting
Conditions
Atypical Endometrial Hyperplasia
Fertility Issues
Overweight and Obesity
Interventions
Behavioral: Intensive Lifestyle Intervention (ILI)
Drug: Megestrol Acetate 160 MG Oral Tablet
Drug: Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg
First Posted Date
2022-04-07
Last Posted Date
2024-07-19
Lead Sponsor
Xiaojun Chen
Target Recruit Count
172
Registration Number
NCT05316493
Locations
🇨🇳

Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

Phase 2
Recruiting
Conditions
Obese
Overweight
Fertility Issues
Endometrial Carcinoma
Interventions
Behavioral: Intensive Lifestyle Intervention (ILI)
Drug: Megestrol Acetate 160 MG Oral Tablet
First Posted Date
2022-04-07
Last Posted Date
2024-08-13
Lead Sponsor
Xiaojun Chen
Target Recruit Count
89
Registration Number
NCT05316467
Locations
🇨🇳

Obstetrics and Gynecology Hospital, Fudan University, Shanghai, Shanghai, China

Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features

Phase 2
Recruiting
Conditions
Endometrial Cancer
Interventions
Drug: Olaparib
Other: Observation
Radiation: Pelvic external beam radiotherapy
Drug: Durvalumab
Drug: Medroxyprogesterone Acetate
Radiation: Vaginal brachytherapy
Drug: Chemotherapy
Drug: Megestrol Acetate
First Posted Date
2022-02-24
Last Posted Date
2024-11-28
Lead Sponsor
Leiden University Medical Center
Target Recruit Count
1615
Registration Number
NCT05255653
Locations
🇨🇦

The POLEmut-BLUE trial: Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

🇳🇱

Medisch Spectrum Twente, Enschede, Netherlands

🇳🇱

The MMRd-GREEN trial: Leiden University Medical Center, Leiden, Netherlands

and more 11 locations
© Copyright 2025. All Rights Reserved by MedPath